Primary Brain Neoplasms (ICD-11: 2A00)

1. Introduction

Primary brain neoplasms represent a heterogeneous group of tumors that originate directly in brain tissue, differentiating themselves from metastases that originate in other organs. These tumors arise from cells of the brain parenchyma itself, including neurons, glial cells, ependymal cells, and other cellular structures that comprise the central nervous system at the encephalic level.

The clinical importance of primary brain neoplasms is significant due to their potential to cause severe neurological dysfunctions, regardless of their benign or malignant nature. The anatomical location of these lesions, confined within the cranial vault, limits therapeutic options and increases the risk of complications related to mass effect, cerebral edema, and compromise of vital functions.

From an epidemiological perspective, primary brain neoplasms represent an important portion of central nervous system tumors, affecting all age groups, from childhood to advanced age. Although they are less frequent than many other types of cancer, their impact on quality of life, morbidity and mortality, and costs to health systems is disproportionate to their prevalence.

Correct coding using the 2A00 code from ICD-11 is critical for multiple reasons: it ensures accuracy in epidemiological records, facilitates resource planning in oncology and neurosurgery, allows appropriate monitoring of clinical outcomes, ensures appropriate reimbursement of procedures and treatments, and contributes to clinical research and development of public health policies aimed at this specific condition.

2. Correct ICD-11 Code

Code: 2A00

Description: Primary brain neoplasms

Parent category: Neoplasms of the brain or central nervous system

Code 2A00 was established in ICD-11 to specifically classify neoplasms that originate in the cerebral parenchyma proper. This code encompasses all primary brain tumors, regardless of their histological type, degree of malignancy, or specific location within the brain.

The hierarchical structure of ICD-11 positions this code as a broad category within central nervous system neoplasms, allowing greater specificity through subcategories that detail the specific histological type of the tumor. This organization facilitates both basic coding and detailed classification when complete histopathological information is available.

Code 2A00 is applicable to both benign and malignant brain tumors, including gliomas, astrocytomas, oligodendrogliomas, ependymomas, medulloblastomas, neuronal and glioneuronal tumors, among others. The defining characteristic is primary origin in brain tissue, differentiating from tumors that originate in the meninges (2A01) or in other structures of the central nervous system outside the brain (2A02).

Correct use of this code requires diagnostic confirmation through advanced imaging methods and, ideally, histopathological confirmation through biopsy or surgical resection. Adequate documentation must specify the primary nature of the neoplasm and its cerebral location.

3. When to Use This Code

Scenario 1: Glioblastoma Multiforme Diagnosed by Neuroimaging and Biopsy

A 58-year-old patient presents with progressive headache, personality changes, and motor deficit in the left hemibody. Brain magnetic resonance imaging demonstrates an expansile lesion with irregular ring enhancement in the right frontal lobe, with significant perilesional edema and mass effect. Stereotactic biopsy confirms glioblastoma multiforme (WHO grade IV). This is a classic case for application of code 2A00, as it is a primary neoplasm originating from glial cells in the brain.

Scenario 2: Low-Grade Astrocytoma in a Young Patient

A 24-year-old patient with a history of recent-onset focal seizures. Investigation with magnetic resonance imaging reveals a hypointense lesion on T1 and hyperintense on T2/FLAIR in the left temporal lobe, without contrast enhancement, suggestive of a low-grade glial tumor. Surgical resection confirms diffuse astrocytoma grade II. Code 2A00 is appropriate because it represents a primary neoplasm of brain tissue, regardless of histological grade.

Scenario 3: Oligodendroglioma with Specific Molecular Characteristics

A 42-year-old patient with seizures and subtle cognitive changes. Neuroimaging shows a lesion in the frontal lobe with characteristic calcifications. Histopathological analysis after resection identifies oligodendroglioma with 1p/19q codeletion, a favorable molecular marker. This case requires code 2A00 because it is a primary cerebral neoplasm originating from oligodendroglial cells.

Scenario 4: Intraventricular Ependymoma

A 6-year-old child presenting with signs of intracranial hypertension (morning headache, vomiting, papilledema). Magnetic resonance imaging identifies a solid mass in the fourth ventricle with obstructive hydrocephalus. Surgical resection and histopathological analysis confirm ependymoma. Although located in the ventricular system, the tumor originates from ependymal cells that line the cerebral ventricles, justifying the use of code 2A00.

Scenario 5: Medulloblastoma in the Posterior Fossa

An 8-year-old pediatric patient with ataxia, dysmetria, and cerebellar signs. Neuroimaging reveals a mass in the cerebellar midline with characteristics of medulloblastoma, confirmed by histopathology after resection. Despite the cerebellar location (posterior fossa), it is a primary neoplasm of brain tissue, specifically of the cerebellum, fitting code 2A00.

Scenario 6: Mixed Glioneuronal Tumor

A 16-year-old adolescent with long-standing refractory epilepsy. Magnetic resonance imaging shows a cystic lesion with a mural nodule in the temporal lobe. Surgical resection and histopathological analysis identify ganglioglioma (a mixed tumor with neuronal and glial components). This primary brain tumor, although with mixed characteristics, is correctly coded as 2A00.

4. When NOT to Use This Code

The code 2A00 should not be used in various specific situations that, although they may involve brain lesions, do not represent primary neoplasms of the cerebral parenchyma:

Brain Metastases: When the brain tumor is secondary to a primary cancer in another organ (lung, breast, melanoma, kidney, colon), the appropriate code for brain metastasis should be used, not 2A00. The distinction is fundamental: code 2A00 is exclusive for tumors that originate in the brain tissue itself.

Meningeal Tumors: Meningiomas and other neoplasms that originate in the meninges (membranes that surround the brain) should be coded as 2A01, not 2A00. Although they may compress the brain and cause neurological symptoms, their origin is meningeal, not cerebral parenchymal.

Spinal Cord Tumors: Primary neoplasms that originate in the spinal cord, even if histologically similar to brain tumors (such as spinal astrocytomas), should be coded as 2A02, respecting the specific anatomical location.

Cranial Nerve Tumors: Schwannomas of the acoustic nerve (acoustic neurinoma) or other tumors that originate in the cranial nerves should not receive code 2A00, but rather 2A02, as they do not originate in the cerebral parenchyma.

Pineal Region Tumors of Non-Cerebral Origin: Germinomas and other germ cell tumors of the pineal region, although located in the brain, originate from germ cells and may require specific coding different from 2A00, depending on detailed classification.

Primary Lymphomas of the Central Nervous System: Although they are primary CNS tumors, lymphomas originate in the lymphoid system and may require specific coding for lymphoid neoplasms, not necessarily 2A00.

Pseudotumoral Lesions: Brain abscesses, granulomas, demyelinating tumefactive lesions, or other inflammatory conditions that simulate tumors should not be coded as 2A00, as they are not true neoplasms.

5. Step-by-Step Coding Process

Step 1: Assess Diagnostic Criteria

The diagnostic confirmation of primary brain neoplasia requires a systematic and multidisciplinary approach. Initially, the presence of an expansile brain lesion must be established through advanced imaging methods, with contrast-enhanced magnetic resonance imaging being the gold standard. Computed tomography can be used as an initial method, especially in emergency situations.

Clinical criteria include neurological signs and symptoms that may vary according to tumor location: progressive headache (especially morning headaches), recent-onset seizures, focal neurological deficits (motor, sensory, visual, or language), cognitive or personality changes, signs of intracranial hypertension (nausea, vomiting, papilledema), or cerebellar symptoms (ataxia, dysmetria).

Histopathological confirmation is fundamental whenever possible, obtained through stereotactic biopsy or surgical resection. Histological analysis determines the cell type, degree of malignancy according to WHO classification, and molecular characteristics that have important prognostic and therapeutic implications.

Essential diagnostic instruments include: contrast-enhanced brain magnetic resonance imaging with advanced sequences (diffusion, perfusion, spectroscopy), positron emission tomography (PET) when available, histopathological analysis with immunohistochemistry, and molecular testing for specific markers (IDH1/2, 1p/19q codeletion, MGMT promoter methylation, among others).

Step 2: Verify Specifiers

After confirming the diagnosis of primary brain neoplasia, it is necessary to document specifiers that may influence management and prognosis. The precise anatomical location must be recorded (frontal lobe, temporal, parietal, occipital, deep structures, cerebellum, brainstem), as it directly impacts therapeutic options.

The specific histological type should be documented when available: astrocytoma (pilocytic, diffuse, anaplastic), glioblastoma, oligodendroglioma, ependymoma, medulloblastoma, primitive neuroectodermal tumor, ganglioglioma, or other less common types. The histological grade according to WHO classification (I to IV) is crucial for prognostic stratification.

Molecular characteristics should be included when known: IDH mutation status, 1p/19q codeletion, MGMT promoter methylation, EGFR amplification, TP53 alterations, among other markers that have specific therapeutic implications.

The patient's functional status should be assessed using scales such as the Karnofsky scale or ECOG, as it influences therapeutic decisions. The extent of surgical resection (total, subtotal, biopsy only) and the presence of leptomeningeal dissemination are also important specifiers.

Step 3: Differentiate from Other Codes

Differentiation from 2A01 (Primary neoplasms of the meninges):

The fundamental distinction lies in cell origin and anatomical location. Code 2A01 applies to tumors that originate in the meningeal layers (dura mater, arachnoid, pia mater), with meningioma being the most common example. These tumors are typically extra-axial, meaning they are located outside the cerebral parenchyma, compressing it externally. On neuroimaging, they present distinct characteristics: dural attachment base, homogeneous enhancement with contrast, "dural tail" sign, and absence of cerebral parenchymal invasion (except in advanced cases). Histologically, they derive from meningothelial cells, not from cerebral tissue cells.

Differentiation from 2A02 (Primary neoplasia of the spinal cord, cranial nerves, or other parts of the CNS):

Code 2A02 is used for primary neoplasias that originate in central nervous system structures outside the brain. This includes tumors of the spinal cord (spinal astrocytomas, spinal ependymomas), tumors of the cranial nerves (acoustic schwannomas, neurofibromas), and tumors of other locations such as the sellar/parasellar region when not originating from cerebral parenchyma. Anatomical location is the main differentiating criterion: if the tumor originates in the cerebral parenchyma (brain proper), use 2A00; if it originates in the spinal cord, cranial nerves, or other CNS structures, use 2A02.

Step 4: Required Documentation

Checklist of Mandatory Information:

• Complete patient identification and diagnosis date
• Detailed clinical presentation with neurological signs and symptoms
• Complete description of neuroimaging findings (modality, sequences, lesion characteristics)
• Precise anatomical location of the neoplasia (lobe, hemisphere, structures involved)
• Pathology report when available (histological type, WHO grade)
• Results of molecular markers when performed
• Extent of disease (localized, multifocal, leptomeningeal dissemination)
• Patient functional status (Karnofsky scale or ECOG)
• Treatments performed or planned (surgery, radiotherapy, chemotherapy)
• Exclusion of metastatic origin (investigation of primary tumor in other organs)

How to Register Appropriately:

The record should begin with explicit confirmation that it is primary brain neoplasia, not metastatic. Document the main diagnostic method (neuroimaging, histopathology) and the date of diagnostic confirmation. Include copies or references to imaging and pathology reports in the medical record.

Use standardized terminology for describing the histological type, following WHO classification for central nervous system tumors. Record ICD-11 code 2A00 clearly, with specific subcategories when applicable and available.

Document the multidisciplinary discussion of the case when performed (tumor board), including therapeutic recommendations. Maintain sequential records of evolution, treatments performed, and therapeutic response, facilitating longitudinal follow-up and outcome studies.

6. Complete Practical Example

Clinical Case

A 52-year-old male patient, previously healthy, seeks neurological evaluation with a three-month history of progressive headache, predominantly in the morning, associated with episodes of nausea. In recent weeks, family members noticed subtle behavioral changes, with increased irritability and difficulty with executive tasks at work. Two weeks ago, he presented with an episode of focal seizure with secondary generalization, which prompted evaluation in the emergency department.

On neurological examination, he was conscious and oriented, but with discrete psychomotor slowing. Fundoscopic examination revealed bilateral papilledema. There was discrete left hemiparesis grade IV, with Babinski sign on the left. Higher cognitive functions showed mild executive impairment and working memory alterations.

Computed tomography of the skull performed in the emergency department demonstrated a hypodense expansile lesion in the right frontal lobe, with perilesional edema and midline shift. Contrast-enhanced cerebral magnetic resonance imaging was then requested, which revealed a heterogeneous lesion 4.5 cm in greatest diameter in the right frontal lobe, with areas of central necrosis, irregular ring enhancement with gadolinium, extensive vasogenic perilesional edema, and mass effect with compression of the right lateral ventricle.

Investigation to exclude primary tumor in other organs included chest and abdominal computed tomography, which revealed no suspicious lesions. Serum tumor markers were negative. The patient underwent right frontal craniotomy with gross total resection of the lesion.

Histopathological analysis revealed high-grade glial neoplasm with high cellularity, marked nuclear atypia, elevated mitotic activity, microvascular proliferation, and palisade necrosis. Immunohistochemistry was positive for GFAP and negative for neuronal markers. The Ki-67 proliferation index was 35%. Molecular analysis demonstrated absence of IDH1/IDH2 mutation and absence of MGMT promoter methylation. Final diagnosis was glioblastoma, WHO grade IV, IDH-wildtype.

Step-by-Step Coding

Criteria Analysis:

1. Confirmed primary cerebral origin: The lesion is located in the cerebral parenchyma (right frontal lobe), with no evidence of primary tumor in other organs after adequate investigation.

2. Histopathological confirmation: Histopathological analysis confirmed high-grade glial neoplasm (glioblastoma), originating from glial cells of the brain.

3. Compatible imaging characteristics: Magnetic resonance imaging showed typical characteristics of high-grade primary cerebral neoplasm (ring enhancement, necrosis, perilesional edema).

4. Exclusion of metastasis: Systemic investigation negative for primary tumor in other organs.

5. Exclusion of meningeal tumors: The lesion is intra-axial (within the cerebral parenchyma), not extra-axial as would be a meningioma.

6. Cerebral location: The tumor is located in the brain proper, not in the spinal cord or cranial nerves.

Code Selected: 2A00 - Primary cerebral neoplasms

Complete Justification:

Code 2A00 is the most appropriate for this case because all criteria for primary cerebral neoplasm have been satisfied. This is a tumor originating in cerebral tissue (glioblastoma derived from glial cells), confirmed by histopathology, with location in the cerebral parenchyma (frontal lobe), with no evidence of metastatic or meningeal origin.

Systemic investigation excluded primary tumor in other organs, confirming the primary nature of the neoplasm. The intra-axial location and histological characteristics confirm this is a tumor of the cerebral parenchyma, not of the meninges (which would be 2A01) nor of the spinal cord or cranial nerves (which would be 2A02).

Applicable Complementary Codes:

• Code for symptomatic epilepsy secondary to tumor (if there is a need to code complications)
• Code for surgical procedure performed (craniotomy and tumor resection)
• Codes for adjuvant treatments when initiated (radiotherapy, chemotherapy)

Documentation should include the specific histological type (glioblastoma, grade IV), molecular characteristics (IDH-wildtype, MGMT unmethylated), precise location (right frontal lobe), and extent of resection (grossly complete), information that may be relevant for more specific subcategories within code 2A00, if available in the classification system used.

7. Related Codes and Differentiation

Within the Same Category

2A01: Primary neoplasms of the meninges

When to use 2A01 vs. 2A00:

The code 2A01 should be used when the tumor originates in the meningeal membranes (dura mater, arachnoid, pia mater) that surround the brain and spinal cord. The most common example is meningioma, which represents the majority of meningeal neoplasms.

Main difference:

The fundamental distinction lies in anatomical origin and relationship with the cerebral parenchyma. Tumors coded as 2A01 are extra-axial, meaning they are located outside the cerebral tissue, compressing it externally. On neuroimaging, they present a clear dural attachment base, well-defined interface with the brain (cleavage plane), and the characteristic "dural tail sign" on magnetic resonance imaging. Histologically, they derive from arachnoid meningothelial cells.

In contrast, tumors coded as 2A00 are intra-axial, originating within the cerebral parenchyma, without a clear cleavage plane with adjacent cerebral tissue. They derive from cells of the nervous tissue itself (neurons, glial cells, ependymal cells).

2A02: Primary neoplasm of the spinal cord, cranial nerves, or other parts of the central nervous system

When to use 2A02 vs. 2A00:

The code 2A02 is applied when the primary neoplasm originates in structures of the central nervous system outside the brain. This includes intramedullary tumors (spinal astrocytomas, spinal ependymomas), cranial nerve tumors (acoustic schwannomas, neurofibromas), and tumors of other specific non-cerebral CNS locations.

Main difference:

The differentiating criterion is purely anatomical: location of tumor origin. If the tumor originates in the cerebral parenchyma (cerebral hemispheres, cerebellum, brainstem when considered part of the brain), 2A00 is used. If it originates in the spinal cord, 2A02 is used, even if the histological type is identical (for example, both may be astrocytomas).

For cranial nerve tumors, such as schwannoma of the vestibulocochlear nerve (acoustic neurinoma), although the lesion may be located in the cerebellopontine angle near the brainstem, the origin is in the cranial nerve, not in the cerebral parenchyma, justifying the use of 2A02.

Differential Diagnoses

Cerebral Metastases:

May present with imaging characteristics similar to primary tumors, especially when multiple. A history of previous neoplasm in another organ is crucial. Metastases tend to be multiple, located at the corticosubcortical junction, and with perilesional edema disproportionate to lesion size.

Cerebral Abscesses:

May simulate tumors with ring enhancement on neuroimaging. They are differentiated by clinical history (fever, leukocytosis, infectious focus), imaging characteristics (more pronounced diffusion restriction, more regular and thin wall), and faster temporal evolution.

Tumefactive Demyelinating Lesions:

Atypical forms of multiple sclerosis or acute disseminated encephalomyelitis may present with expansile lesions that simulate tumors. History of previous relapses, presence of other demyelinating lesions, and specific imaging characteristics help with differentiation.

Primary Central Nervous System Lymphoma:

Although technically a primary CNS neoplasm, lymphoma originates in the lymphoid system and presents with distinct characteristics: intense homogeneous enhancement, periventricular or basal ganglia location, and dramatic response to corticosteroids. It may require specific coding for lymphoid neoplasms.

8. Differences with ICD-10

In ICD-10, primary brain neoplasms were coded mainly in category C71, which specified "Malignant neoplasm of the brain," with anatomical subdivisions (C71.0 to C71.9) based on specific location within the brain. Benign brain tumors were coded as D33.0-D33.2.

Main changes in ICD-11:

ICD-11 introduces a more integrated and logical organization of neoplasms of the central nervous system. Code 2A00 encompasses all primary brain neoplasms, regardless of biological behavior (benign or malignant), representing an important philosophical shift. In ICD-10, there was rigid separation between malignant neoplasms (C71) and benign ones (D33), which did not always adequately reflect the clinical reality of brain tumors.

ICD-11 allows greater specificity through subcategories that can detail the specific histological type, degree of malignancy, and molecular characteristics, aligning better with the modern WHO classification for central nervous system tumors. This approach recognizes that even histologically "benign" tumors may have clinically significant behavior due to their location.

Another important change is the clearer separation between tumors of the cerebral parenchyma (2A00), meningeal tumors (2A01), and tumors of other CNS locations (2A02), facilitating precise coding based on anatomical origin.

Practical impact of these changes:

For healthcare professionals, the transition to ICD-11 requires adaptation in how brain neoplasms are documented and coded. The integrated approach may simplify initial coding, but requires attention to ensure that appropriate subcategories are used when available.

For health information systems, the change may impact historical statistics, requiring careful mapping between ICD-10 and ICD-11 codes to maintain continuity of epidemiological data. The greater potential specificity of ICD-11 may improve the quality of cancer registries and facilitate clinical research.

For health managers and planners, the new classification may provide more precise data on the actual disease burden of brain neoplasms, including low-grade tumors that were previously classified separately as "benign," but still require significant resources for treatment and follow-up.

9. Frequently Asked Questions

1. How is the diagnosis of primary brain neoplasms made?

The diagnosis involves multiple stages. It begins with clinical evaluation of suspicious neurological signs and symptoms (progressive headache, seizures, focal neurological deficits, cognitive changes). The main diagnostic method is neuroimaging, with contrast-enhanced brain magnetic resonance imaging being the examination of choice, as it provides superior anatomical details, characterizes the lesion, and aids in therapeutic planning. Computed tomography can be used initially, especially in emergency situations. Definitive confirmation requires histopathological analysis through stereotactic biopsy or surgical resection, which determines the specific cell type, degree of malignancy, and molecular characteristics important for prognosis and treatment.

2. Is treatment available in public health systems?

Treatment of primary brain neoplasms is generally available in public health systems in most countries, although access may vary depending on case complexity and local resources. Typical multimodal treatment includes neurosurgery for resection or biopsy, radiotherapy, and chemotherapy, which are considered standard treatments. Specialized neuro-oncology centers offer multidisciplinary approaches with neurosurgeons, neuro-oncologists, radiation oncologists, and support teams. Access to newer therapies, such as molecular targeted therapies or immunotherapy, may be more limited and vary significantly among different regions and health systems.

3. How long does treatment last?

Treatment duration varies widely depending on histological type, degree of malignancy, and therapeutic response. The initial surgical phase (resection or biopsy) is a single event, followed by post-operative recovery lasting several weeks. Adjuvant radiotherapy, when indicated, typically lasts 6 weeks with daily sessions. Chemotherapy may extend for 6 to 12 months or longer, depending on the specific protocol. For high-grade tumors such as glioblastoma, combined adjuvant treatment (radiotherapy with concurrent chemotherapy followed by maintenance chemotherapy) may last approximately one year. Low-grade tumors may require only surveillance after resection, or less intensive treatments. Long-term follow-up with periodic neuroimaging is necessary indefinitely to monitor recurrence.

4. Can this code be used in medical certificates?

Yes, code 2A00 can and should be used in medical certificates when appropriate, especially to document work leave or justify need for treatments and procedures. Medical documentation should include the ICD-11 code along with clear description of the diagnosis. It is important to note that code specificity may be relevant for social security benefits or health insurance purposes, therefore, when available, using subcategories that specify histological type and degree of malignancy may be beneficial. Medical confidentiality must be respected, providing sufficient information for necessary administrative purposes without exposing unnecessary details.

5. What are the most common symptoms that should alert to possible brain neoplasm?

Symptoms vary according to tumor location and growth rate. Headache is the most common symptom, especially when progressive, worse in the morning, or associated with vomiting. Seizures of recent onset in adults without previous history are highly suspicious. Focal neurological deficits such as weakness on one side of the body, visual changes, speech or language difficulties, or coordination problems should always be investigated. Cognitive or personality changes, especially when progressive, may indicate frontal tumors. Symptoms of intracranial hypertension (headache, nausea, vomiting, visual changes, papilledema) suggest significant mass effect. It is important to emphasize that many of these symptoms are nonspecific and may have other causes, but their presence, especially when progressive or combined, warrants appropriate neurological investigation.

6. Is there a difference in prognosis among different types of primary brain tumors?

Yes, prognosis varies dramatically among different histological types and degrees of malignancy. Low-grade tumors (WHO grades I and II), such as pilocytic astrocytomas or low-grade oligodendrogliomas, generally have favorable prognosis, especially when amenable to complete resection, with survival measured in decades. Grade III tumors (anaplastic) have intermediate prognosis, with median survival of several years. Glioblastomas (grade IV) have more guarded prognosis, with median survival of 15 to 18 months even with aggressive treatment, although some patients live significantly longer. Molecular characteristics also strongly influence prognosis: tumors with IDH mutation or 1p/19q codeletion have better prognosis than their counterparts without these alterations. Patient age, functional status, and extent of surgical resection are also important prognostic factors.

7. Is it necessary to repeat biopsy if the tumor recurs?

Rebiopsy at recurrence is often recommended, although it is not mandatory in all cases. Histological analysis at recurrence may reveal transformation to higher grade (for example, low-grade astrocytoma transforming into glioblastoma), changes that significantly influence therapeutic options. Furthermore, molecular analysis at recurrence may identify new genetic alterations that may be targets for specific therapies. The decision to perform rebiopsy depends on several factors: location and accessibility of the recurrent lesion, patient's clinical condition, potential impact on therapeutic management, and procedure risks. In some cases, especially when recurrence is typical and the patient has already been extensively treated, empirical treatment without new biopsy may be chosen.

8. What is the role of molecular characteristics in diagnosis and treatment?

Molecular characteristics have revolutionized the management of brain neoplasms in recent decades. Modern WHO classification integrates molecular characteristics with traditional histology to define diagnostic entities. Markers such as IDH1/IDH2 mutation distinguish gliomas with better prognosis and are essential for accurate classification. 1p/19q codeletion defines true oligodendrogliomas and predicts favorable response to chemotherapy. MGMT promoter methylation predicts response to temozolomide chemotherapy in glioblastomas. Other molecular alterations (EGFR amplification, TP53 mutations, BRAF alterations, specific gene fusions) have diagnostic, prognostic, and therapeutic implications. Increasingly, targeted therapies are being developed for specific molecular alterations, making molecular characterization not only diagnostic but also guiding personalized treatment. Molecular analysis should be performed whenever possible in primary brain tumors.

---

Conclusion:

Appropriate coding of primary brain neoplasms using ICD-11 code 2A00 is fundamental to ensure accurate records, adequate resource planning, and appropriate epidemiological follow-up. Clear distinction between primary tumors of the cerebral parenchyma, meningeal tumors, and tumors of other central nervous system locations is essential for correct code application. Diagnosis requires a multidisciplinary approach with advanced neuroimaging and histopathological confirmation whenever possible, including molecular characterization that increasingly influences prognosis and treatment. The transition from ICD-10 to ICD-11 brings important changes in classification organization, better reflecting the complexity and heterogeneity of primary brain neoplasms.

External References

This article was prepared based on reliable scientific sources:

1. 🌍 WHO ICD-11 - Primary brain neoplasms
2. 🔬 PubMed Research on Primary brain neoplasms
3. 🌍 WHO Health Topics
4. 📊 Clinical Evidence: Primary brain neoplasms
5. 📋 Ministry of Health - Brazil
6. 📊 Cochrane Systematic Reviews

References verified on 2026-02-04